var data={"title":"Dabrafenib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dabrafenib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/578151?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dabrafenib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dabrafenib: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617042\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tafinlar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21737061\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Tafinlar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20498983\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, BRAF Kinase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608805\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Confirm BRAF V600 mutation status prior to treatment initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melanoma (metastatic or unresectable) (with BRAF V600E mutation):</b> Oral: 150 mg twice daily (approximately every 12 hours) (single-agent therapy); continue until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melanoma (metastatic or unresectable) (with BRAF V600E or BRAF V600K mutation):</b> Oral: 150 mg twice daily (approximately every 12 hours (in combination with trametinib); continue until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-small cell lung cancer (metastatic) (with BRAF V600E mutation): </b>Oral: 150 mg twice daily, approximately every 12 hours (in combination with trametinib); continue until disease progression or unacceptable toxicity (Planchard 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Missed doses:</i> A missed dose may be administered up to 6 hours prior to the next dose; do not administer if &lt;6 hours until the next dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608806\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608807\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment (GFR &ge;30 mL/minute/1.73 m<sup>2</sup>): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608808\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate to severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, metabolism is primarily hepatic and exposure may be increased in patients with moderate to severe impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608809\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Recommended dabrafenib dose reductions for toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">First dose reduction: 100 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Second dose reduction: 75 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Third dose reduction: 50 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Subsequent modifications (if unable to tolerate 50 mg twice daily): Permanently discontinue.</p>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> If using combination therapy, refer to Trametinib monograph for recommended trametinib dose reductions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cardiac:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;20% absolute decrease in LVEF from baseline and LVEF is below institutional LLN: Interrupt dabrafenib therapy; if improved, may resume at the same dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Symptomatic heart failure: Interrupt dabrafenib therapy; if improved, may resume at the same dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dermatologic:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intolerable grade 2 skin toxicity or grade 3 or 4 skin toxicity: Interrupt dabrafenib therapy for up to 3 weeks. If toxicity improves within 3 weeks, resume at a lower dose level. If toxicity does not improve within 3 weeks following therapy interruption, permanently discontinue dabrafenib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">New primary cutaneous malignancy: No dabrafenib dosage modification is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fever:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fever of 38.5&deg;C to 40&deg;C (101.3&deg;F to 104&deg;F): Interrupt dabrafenib therapy until temperature normalizes. Resume at the same or lower dose level.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fever &gt;40&deg;C (104&deg;F) and/or fever complicated by rigors, hypotension, dehydration, or renal failure: Interrupt dabrafenib therapy until temperature normalizes. Resume at a lower dose level or permanently discontinue. May require prophylactic antipyretics (secondary prophylaxis) upon resumption. Administer corticosteroids (eg, prednisone 10 mg daily or equivalent) for at least 5 days for second or subsequent pyrexia if temperature does not return to baseline within 3 days of onset of fever, or for fever associated with complications (eg, dehydration, renal failure,  hypotension, or severe chills/rigors with no evidence of active infection).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemorrhage:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 hemorrhage: Interrupt dabrafenib therapy. If hemorrhage improves, resume at a lower dose level. If hemorrhage does not improve following therapy interruption, permanently discontinue dabrafenib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4 hemorrhage: Permanently discontinue dabrafenib.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ocular:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Uveitis including iritis and iridocyclitis: If mild or moderate uveitis does not respond to local ocular therapy (or for severe uveitis), interrupt dabrafenib therapy for up to 6 weeks. If improves to &le; grade 1 within 6 weeks following therapy interruption, resume at the same dose or a lower dose. If does not improve, or for persistent grade 2 or higher uveitis of &gt;6 week duration, permanently discontinue dabrafenib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 2 or 3 retinal pigment epithelial detachments (RPED): No dabrafenib dosage modification is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Retinal vein occlusion: No dabrafenib dosage modification is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary:</b> Interstitial lung disease or pneumonitis: No dabrafenib dosage modification is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Venous thromboembolism:</b> Uncomplicated DVT or PE: No dabrafenib dosage modification is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Other toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intolerable grade 2 or any grade 3 toxicity: Interrupt dabrafenib therapy until resolution to &le; grade 1; resume at a lower dose level. If toxicity does not improve following therapy interruption, permanently discontinue dabrafenib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4 toxicity (first occurrence): Interrupt dabrafenib therapy until resolution to &le; grade 1; consider resuming at a lower dose level or permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4 toxicity (recurrent after dosage reduction): Permanently discontinue dabrafenib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">New primary noncutaneous malignancy (RAS mutation-positive): Permanently discontinue dabrafenib.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617043\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tafinlar: 50 mg, 75 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608782\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608780\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM354532.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WVVuf0QlddtkerVKjMxIE9Q==&amp;TOPIC_ID=89686\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM354532.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608811\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer orally at least 1 hour before or 2 hours after a meal; doses should be ~12 hours apart. Do not open, crush, or break capsules. A missed dose may be administered up to 6 hours prior to the next dose. When administered in combination with trametinib, take the once-daily dose of trametinib at the same time each day with either the morning or evening dose of dabrafenib.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104466\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20498985\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melanoma (metastatic or unresectable):</b> Treatment of unresectable or metastatic melanoma in patients with a BRAF V600E mutation (single agent therapy) or in patients with BRAF V600E or BRAF V600K mutations (in combination with trametinib); confirm BRAF V600E or BRAF V600K mutation status with an approved test prior to treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-small cell lung cancer (metastatic)</b>: Treatment of metastatic non-small cell lung cancer (NSCLC) in patients with BRAF V600E mutation as detected by an approved test (in combination with trametinib).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Not indicated for treatment of patients with wild-type BRAF melanoma or wild-type BRAF NSCLC.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608778\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dabrafenib may be confused with cobimetinib, dasatinib, trametinib, vemurafenib</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20713630\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Monotherapy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Peripheral edema (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Fatigue (40%), headache (28% to 32%), chills (17%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Dermatological reaction (68%), skin rash (17% to 53%), hyperkeratosis (37%), alopecia (22%), palmar-plantar erythrodysesthesia (20%), pruritus (13%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Hyperglycemia (49% to 50%; grades 3/4: 2% to 6%), hypophosphatemia (37% to 40%), increased gamma-glutamyl transferase (38%), hyponatremia (8% to 36%), hypoalbuminemia (23%), hypokalemia (23%), hyperkalemia (15%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Diarrhea (28%), abdominal pain (21%), nausea (21%), decreased appetite (19%), vomiting (15%), constipation (11%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Lymphocytopenia (40%; grades 3/4: 6%), anemia (28%), papilloma (27%), leukopenia (21%), malignant neoplasm of skin (keratoacanthoma and squamous cell carcinoma; 7% to 19%; grades 3/4: 4%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hepatic: Increased serum alkaline phosphatase (19% to 26%), increased serum AST (15%), increased serum ALT (11%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Arthralgia (27% to 34%), myalgia (11% to 23%), limb pain (19%), back pain (11% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Cough (12% to 21%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miscellaneous: Fever (26% to 28%; grades 3/4: &le;4%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Prolonged Q-T interval on ECG (&gt;60 msec from baseline: 2%; &gt;500 msec: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Dizziness (9%), insomnia (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Actinic keratosis (9%), night sweats (6%), xeroderma (6%), acneiform eruption (4%), erythema (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Hypocalcemia (9%), hypomagnesemia (6%), hypercalcemia (4%), dehydration (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Pancreatitis (&lt;10%), xerostomia (6%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Genitourinary: Urinary tract infection (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Neutropenia (9%; grades 3/4: 2%), thrombocytopenia (8%), basal cell carcinoma (2%), hemorrhage (2%), malignant melanoma (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hypersensitivity: Hypersensitivity (bullous rash, &lt;10%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Muscle spasm (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ophthalmic: Uveitis (including iritis, 1%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Renal: Interstitial nephritis (&lt;10%), increased serum creatinine (9%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Nasopharyngitis (10%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miscellaneous: Febrile reaction (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Combination therapy with trametanib:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Peripheral edema (28% to 31%), prolonged Q-T interval on ECG (&gt;60 msec from baseline: 13%; &gt;500 msec: 4%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Chills (50% to 58%), fatigue (53% to 57%), headache (29% to 37%), insomnia (11% to 18%), dizziness (13% to 16%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Dermatological reaction (65%; 3% required hospitalization), skin rash (43% to 45%), night sweats (15% to 24%), xeroderma (9% to 18%), acneiform eruption (11% to 16%), actinic keratosis (7% to 15%), erythema (6% to 15%), pruritus (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Hyperglycemia (58% to 67%; grades 3/4: 5% to 6%), increased gamma-glutamyl transferase (54% to 56%), hyponatremia (48% to 55%), hypoalbuminemia (43% to 53%), hypophosphatemia (41% to 47%), hypokalemia (15% to 29%), hyperkalemia (18% to 22%), hypocalcemia (13% to 20%), hypercalcemia (15% to 19%), hypomagnesemia (2% to 18%), dehydration (6% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Nausea (44% to 46%), vomiting (40% to 43%), diarrhea (26% to 36%), abdominal pain (24% to 33%), decreased appetite (22% to 30%), constipation (17% to 22%), xerostomia (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Genitourinary: Urinary tract infection (6% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Leukopenia (46% to 62%; grades 3/4: 4% to 5%), lymphocytopenia (55% to 59%; grades 3/4: 19% to 22%), anemia (46% to 55%; grades 3/4: 4% to 7%), neutropenia (37% to 55%; grades 3/4: 2% to 13%), thrombocytopenia (31%; grades 3/4: 2% to 4%), hemorrhage (11% to 16%; major hemorrhage [intracranial or gastric]: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hepatic: Increased serum alkaline phosphatase (60% to 67%), increased serum AST (54% to 60%), increased serum ALT (35% to 42%), hyperbilirubinemia (7% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Arthralgia (27% to 44%), myalgia (22% to 24%), back pain (11% to 18%), limb pain (11% to 16%), muscle spasm (2% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Renal: Increased serum creatinine (20% to 24%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Cough (11% to 29%), oropharyngeal pain (7% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miscellaneous: Fever (57% to 71%; grades 3/4: 5% to 9%), febrile reaction (25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Hypertension (&lt;10%), cardiomyopathy (&le;9%), venous thromboembolism (deep vein thrombosis or pulmonary embolism; 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Cellulitis (&lt;10%), folliculitis (&lt;10%), hyperhidrosis (&lt;10%), hyperkeratosis (&lt;10%), palmar-plantar erythrodysesthesia (&lt;10%), paronychia (&lt;10%), pustular rash (&lt;10%), secondary skin infection (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Hyperglycemia (grade 3: 5% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Pancreatitis (&lt;10%), stomatitis (&lt;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Cutaneous papilloma (&lt;10%), basal cell carcinoma (9%), malignant neoplasm of skin (keratoacanthoma and squamous cell carcinoma; 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Weakness (&lt;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ophthalmic: Blindness (transient; &lt;10%), blurred vision (&lt;10%), retinal detachment (pigment epithelium; 1%), uveitis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Renal: Renal failure (2% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%: Glioblastoma, Kaposi sarcoma, malignant neoplasm of colon and rectum (recurrent NRAS mutation-positive), malignant neoplasm of head and neck, pancreatic adenocarcinoma (KRAS mutation-positive)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20498986\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Canadian labeling:</i> Hypersensitivity to dabrafenib or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608787\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiomyopathy: Cardiomyopathy may occur when used as a single agent or in combination with trametinib. The median time to onset of cardiomyopathy in patients with melanoma was ~8 months (range: 28 days to ~25 months) when used in combination with trametinib, and ~4 months (range: 28 days to ~19 months) for single agent therapy. The median time of onset of cardiomyopathy in patients with NSCLC was 6.7 months (range: 1.4 to 14.1 months). Assess LVEF (by echocardiogram or MUGA scan) prior to combination therapy initiation, at 1 month, and then at 2- to 3-month intervals while on therapy. Cardiac dysfunction may require dabrafenib treatment interruption (see trametinib monograph for dosage modifications). Cardiomyopathy resolved in some patients following dose adjustments, treatment interruption or permanent discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: Serious dermatologic toxicity (eg, rash, dermatitis, acneiform rash, palmar-plantar erythrodysesthesia syndrome, erythema) may occur when used in combination with trametinib (known complication of single-agent trametinib therapy); some patients required hospitalization for severe toxicity or for secondary skin infections. In melanoma studies, the median time to onset and resolution of skin toxicity for combination therapy was 2 months (range: 1 day to 22 months) and 1.2 months (range: 1 day to ~24 months), respectively. Monitor for dermatologic toxicity and signs/symptoms of secondary infections. Treatment interruption, dose reduction, and/or therapy discontinuation may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Febrile reactions: Serious febrile reactions and fever (any severity) complicated by hypotension, rigors or chills, dehydration, or renal failure were observed in melanoma studies during dabrafenib single-agent therapy and when used in combination with trametinib. The incidence and severity were higher with combination therapy than with single-agent dabrafenib. The median time to initial fever (single-agent therapy) was 11 days (range: 1 day to 6.6 months); median duration was 3 days (range: 1 day to 4.2 months). In patients treated with combination therapy, the median time to onset of fever was 1 month (range: 1 day to 23.5 months) and the median duration was 3 days (range: 1 day to 11.3 months). Interrupt dabrafenib therapy for fever &ge;38.5&deg;C (101.3&deg;F) or for any other serious febrile reaction complicated by hypotension, rigors/chills, dehydration, or renal failure; evaluate promptly for signs/symptoms of infection. Dosage reduction (or discontinuation) may be required; when resuming therapy after a febrile reaction, may require administration of antipyretics as secondary prophylaxis. Administer corticosteroids (eg, prednisone 10 mg daily or equivalent) for at least 5 days for second or subsequent episodes of pyrexia if temperature does not return to baseline within 3 days of fever onset, or for pyrexia associated with complications (eg, dehydration, hypotension, severe chills/rigors with no evidence of active infection).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemorrhage: Hemorrhage, including symptomatic bleeding in a critical area/organ, may occur with dabrafenib either as a single agent or in combination with trametinib. Major bleeding events (some fatal) included intracranial or gastrointestinal hemorrhage. May require treatment interruption and dosage reduction; permanently discontinue dabrafenib (and trametinib) for all grade 4 hemorrhagic events and any grade 3 event that does not improve with therapy interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia: Hyperglycemia may occur while on therapy (either as a single agent or in combination with trametinib); may require initiation of insulin or oral hypoglycemic agent therapy (or an increased dose if already taking). Monitor serum glucose at baseline and as clinically necessary in patients with preexisting diabetes or hyperglycemia. Instruct patients to report symptoms of severe hyperglycemia (eg, polydipsia, polyuria).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: Cutaneous squamous cell carcinoma and keratoacanthoma (cuSCC) and new primary melanoma were observed during single-agent dabrafenib therapy at an increased incidence compared with control therapy in clinical trials. In melanoma, the median time to the first occurrence of cuSCC was 2.1 months (range: 1 to 53 weeks); approximately one-third of patients who developed cuSCC had more than one occurrence (with continued treatment). The median time between diagnosis of the first and second lesions was 6 weeks. When used in combination with trametinib for the treatment of melanoma, cuSCC occurred less frequently than with single-agent dabrafenib therapy; time to diagnosis ranged from 1.8 to 16.8 months after the initiation of combination treatment, and from 9 days to ~21 months for single-agent therapy. Cases of cuSCC also occurred in patients with NSCLC, with a first occurrence onset ranging from 25 days to ~12 months. Basal cell carcinoma (BCC) may also occur with combination or single-agent therapy; the incidence of BCC is ~3% for combination therapy versus 6% for single-agent dabrafenib. The time to BCC diagnosis ranged from ~3 to ~24 months for melanoma patients receiving combination therapy. Dermatologic evaluations should be performed prior to initiating therapy, every 2 months during therapy, and for up to 6 months post discontinuation. There are case reports of noncutaneous malignancies, including pancreatic cancer (KRAS mutation-positive), colorectal cancer (recurrent NRAS mutation-positive), hand and neck cancer, and glioblastoma, with combination therapy; monitor for signs/symptoms of noncutaneous malignancies. Dabrafenib should be permanently discontinued if RAS mutation-positive noncutaneous malignancies develop (no trametinib dosage reduction is required).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular toxicity: Retinal pigment epithelial detachments (RPED) were seen in melanoma clinical trials when used in combination with trametinib (a known complication of trametinib single-agent therapy). Detachments were typically bilateral and multifocal and occurred in the central macular area of the retina. Promptly (within 24 hours) refer patients for ophthalmological evaluations if loss of vision or other visual disturbances occur; dabrafenib dosage modification is not necessary for RPED (trametinib therapy modification may be required). Ophthalmic exams (including retinal evaluation) should be performed periodically during treatment with combination therapy. Uveitis, including iritis and iridocyclitis, has been reported with dabrafenib single-agent therapy and when used in combination with trametinib; manage symptomatically with local ophthalmic steroid and mydriatic drops. May require dabrafenib treatment interruption or permanent discontinuation (does not require alteration in trametinib therapy). Monitor for signs/symptoms of uveitis (eg, eye pain, photophobia, vision changes).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: QTcF prolongation &gt;60 msec above baseline or to &gt;500 msec was reported (rare), both as a single agent or when used in combination with trametinib. Use with caution in patients who may be at increased risk for arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Venous thromboembolism: Venous thromboembolism events (some fatal) may occur when dabrafenib is used in combination with trametinib. DVT and PE occurred at an increased incidence with combination therapy. Patients should seek immediate medical attention with symptoms of DVT or PE (shortness of breath, chest pain, arm/leg swelling). Dabrafenib therapy may be continued for uncomplicated DVT or PE; permanently discontinue trametinib for life-threatening PE.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Combination therapy with trametinib: Serious adverse reactions (retinal vein occlusion, interstitial lung disease) that occur with single-agent trametinib may also occur when dabrafenib is administered in combination with trametinib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drugs affecting gastric pH: Drugs affecting gastric pH (eg, proton pump inhibitors, H<sub>2</sub>-receptor antagonists, antacids) may alter dabrafenib solubility, resulting in decreased bioavailability. Clinical trials have not been performed to evaluate concomitant administration and its effect on dabrafenib efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glucose-6-phosphate dehydrogenase deficiency: Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at risk for hemolytic anemia when administered dabrafenib; use with caution and closely observe for signs/symptoms of hemolytic anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Appropriate use: Not indicated for treatment of patients with wild-type BRAF melanoma or wild-type BRAF NSCLC. Exposing wild-type cells to BRAF inhibitors such as dabrafenib may result in paradoxical activation of MAP-kinase signaling and increased cell proliferation. Prior to initiating therapy, confirm BRAF V600E or BRAF V600K mutation status with an approved test. Data regarding single agent use for melanoma in patients with BRAF V600K mutation is limited; compared to BRAF V600E mutation, lower response rates have been observed with BRAF V600K mutation. Data regarding other less common BRAF V600 mutations in melanoma is lacking.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20797138\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2, CYP2C8 (major), CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BCRP/ABCG2, OATP1B1/SLCO1B1; <b>Induces</b> CYP2C9 (weak), CYP3A4 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20797136\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=89686&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Dabrafenib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Axitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bedaquiline: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bedaquiline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobimetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2B6 Substrates (High risk with Inducers): Dabrafenib may decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Substrates (High risk with Inducers): Dabrafenib may decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers).  Management: Seek alternatives to the CYP2C19 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C8 Inhibitors (Moderate): May decrease the metabolism of CYP2C8 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C8 Inhibitors (Strong): May increase the serum concentration of Dabrafenib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C8 Substrates (High risk with Inducers): Dabrafenib may decrease the serum concentration of CYP2C8 Substrates (High risk with Inducers).  Management: Seek alternatives to the CYP2C8 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Substrates (High risk with Inducers): Dabrafenib may decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).  Management: Seek alternatives to the CYP2C9 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Dabrafenib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Dabrafenib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inducers): Dabrafenib may decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).  Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daclatasvir.  Management: Increase the daclatasvir dose to 90 mg once daily if used with a moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasabuvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dasabuvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP2C8 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deflazacort: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elbasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elbasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estriol (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Estriol (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estriol (Topical): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Estriol (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Dabrafenib may decrease the serum concentration of Estrogen Derivatives (Contraceptive).  Management: Females of reproductive potential should use an alternative, highly effective, non-hormonal means of contraception during and at least 2 weeks (dabrafenib alone) or 4 months (dabrafenib + trametinib) after discontinuation of dabrafenib treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glecaprevir and Pibrentasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grazoprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Grazoprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of GuanFACINE.  Management: Increase the guanfacine dose by up to double when initiating concomitant therapy with moderate CYP3A4 inducers. Increase guanfacine dose gradually over 1-2 weeks if moderate CYP3A4 inducer therapy is just beginning.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May decrease the serum concentration of Dabrafenib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May increase the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor may decrease the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lurasidone.  Management: Monitor for decreased lurasidone effects if combined with moderate CYP3A4 inducers and consider increasing the lurasidone dose if coadministered with a moderate CYP3A4 inducer for 7 or more days.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nisoldipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olaparib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palbociclib.  Management: The US label does not provide specific recommendations concerning use with moderate CYP3A4 inducers, but the Canadian label recommends avoiding use of moderate CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Perampanel.  Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used concurrently with moderate and strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Dabrafenib may decrease the serum concentration of Progestins (Contraceptive).  Management: Females of reproductive potential should use an alternative, highly effective, non-hormonal means of contraception during and at least 2 weeks (dabrafenib alone) or 4 months (dabrafenib + trametinib) after discontinuation of dabrafenib treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May decrease the serum concentration of Dabrafenib. Dabrafenib may decrease the serum concentration of Proton Pump Inhibitors. Management: Seek alternatives to the proton pump inhibitor when possible.  If concomitant therapy cannot be avoided, monitor for diminished effects of both drugs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sonidegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Dabrafenib. Management: Seek alternatives to St. John's wort when possible.  If concomitant therapy cannot be avoided, monitor closely for diminished therapeutic effects of dabrafenib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trametinib: May enhance the adverse/toxic effect of Dabrafenib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Venetoclax. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608789\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Administration with a high-fat meal decreased C<sub>max </sub>and AUC by 51% and 31%, respectively, and delayed median T<sub>max </sub>by ~4 hours. Management: Administer 1 hour before or 2 hours after a meal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608784\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were observed in animal reproduction studies. Based on its mechanism of action, dabrafenib would be expected to cause fetal harm if administered to a pregnant woman. Females of reproductive potential should use a highly effective nonhormonal contraceptive during therapy and for at least 2 weeks for single-agent therapy or 4 months for combination therapy with trametinib after treatment is complete; hormonal contraceptives may not be effective. Spermatogenesis may be impaired in males (observed in animal studies); family planning and fertility counseling should be considered prior to therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608786\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if dabrafenib is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 2 weeks (single agent therapy) or 4 months (combination therapy with trametinib) after the last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608813\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;\">BRAFV600 mutation status (prior to treatment); serum glucose (particularly in patients with preexisting diabetes mellitus or hyperglycemia); electrolytes; renal function; dermatologic evaluations prior to initiation, every 2 months during therapy, and for up to 6 months following discontinuation to assess for new cutaneous malignancies; monitor for febrile drug reactions and signs/symptoms of infections; signs/symptoms of uveitis (eg, eye pain, photophobia, vision changes), monitor for signs/symptoms of hemolytic anemia.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients receiving combination therapy with trametinib: Hepatic function; CBC (baseline and periodically during therapy); assess LVEF (by echocardiogram or MUGA scan) at baseline, 1 month after therapy initiation, and then at 2- to 3-month intervals; monitor for signs/symptoms of hemorrhage, venous thromboembolism, interstitial lung disease, and RPED, or retinal vein occlusion.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Monitor adherence.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608792\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Dabrafenib selectively inhibits some mutated forms of the protein kinase B-raf (BRAF). BRAF V600 mutations result in constitutive activation of the BRAF pathway; through BRAF inhibition, dabrafenib inhibits tumor cell growth. The combination of dabrafenib and trametinib allows for greater inhibition of the MAPK pathway, resulting in BRAF V600 melanoma cell death (Flaherty 2012). Dabrafenib plus trametinib has been reported to synergistically inhibit cell growth in lung cancer cell lines which are BRAF V600E-mutant (Planchard 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608794\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Decreased with a high-fat meal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: 70.3 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 99.7% to plasma proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP2C8 and CYP3A4 to hydroxy-dabrafenib (active) which is further metabolized via CYP3A4 oxidation to desmethyl-dabrafenib (active)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 95%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Parent drug: 8 hours; Hydroxy-dabrafenib (active metabolite): 10 hours; Desmethyl-dabrafenib (active metabolite): 21 to 22 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 2 hours; delayed with a high-fat meal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (71%); urine (23%; metabolites only) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22686899\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Tafinlar Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (120): $8,814.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (120): $11,916.95</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23777406\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Tafinlar (AT, AU, BB, BE, BM, CH, CY, CZ, DE, DK, EE, ES, FR, GB, HK, HR, HU, IE, IL, IS, JP, KR, LT, LU, MT, NL, NO, NZ, PL, PT, RO, SE, SG, SI, SK, TH, UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Anforth RM, Blumetti TC, Kefford RF, et al, &ldquo;Cutaneous Manifestations of Dabrafenib (GSK2118436): A Selective Inhibitor of Mutant BRAF in Patients With Metastatic Melanoma,&rdquo; <i>Br J Dermatol</i>, 2012, 167(5):1153-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/22804352/pubmed\" target=\"_blank\" id=\"22804352\">22804352</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Falchook GS, Long GV, Kurzrock R, et al, &ldquo;Dabrafenib in Patients With Melanoma, Untreated Brain Metastases, and Other Solid Tumours: A Phase 1 Dose-Escalation Trial,&rdquo; <i>Lancet</i>, 2012, 379(9829):1893-901.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/22608338/pubmed\" target=\"_blank\" id=\"22608338\">22608338</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flaherty KT, Infante JR, Daud A, et al, &ldquo;Combined BRAF and MEK Inhibition in Melanoma With BRAF V600 Mutations,&rdquo; <i>N Engl J Med</i>, 2012, 367(18):1694-703.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/23020132/pubmed\" target=\"_blank\" id=\"23020132\">23020132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hauschild A, Grob JJ, Demidov LV, et al, &ldquo;Dabrafenib in BRAf-Mutated Metastatic Melanoma: A Multicenter, Open-Label, Phase 3 Randomised Controlled Trial,&rdquo; <i>Lancet</i>, 2012, 380(9839):358-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/22735384/pubmed\" target=\"_blank\" id=\"22735384\">22735384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hong DS, Vence L, Falchook G, et al, &ldquo;BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency,&rdquo; <i>Clin Cancer Res</i>, 2012, 18(8):2326-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/22355009/pubmed\" target=\"_blank\" id=\"22355009\">22355009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-451.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/26037941/pubmed\" target=\"_blank\" id=\"26037941\">26037941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Long GV, Trefzer U, Davies MA, et al, &ldquo;Dabrafenib in Patients With Val600Glu or Val600Lys BRAF-Mutant Melanoma Metastatic to the Brain (BREAK-MB): A Multicenter, Open-Label, Phase 2 Trial,&rdquo; <i>Lancet Oncol</i>, 2012, 13(11):1087-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/23051966/pubmed\" target=\"_blank\" id=\"23051966\">23051966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mekinist (trametinib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27283860\"></a>Planchard D, Besse B, Groen HJ, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. <i>Lancet Oncol</i>. 2016;17(7):984-993.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabrafenib-drug-information/abstract-text/27283860/pubmed\" target=\"_blank\" id=\"27283860\">27283860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tafinlar (dabrafenib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tafinlar (dabrafenib) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 4, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 89686 Version 132.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F20617042\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F21737061\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F20498983\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F20608805\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F20608806\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20608807\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20608808\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F20608809\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F20617043\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F20608782\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F20608780\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F20608811\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104466\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F20498985\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F20608778\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F20713630\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F20498986\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F20608787\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F20797138\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F20797136\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F20608789\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F20608784\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20608786\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F20608813\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F20608792\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F20608794\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F22686899\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23777406\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/89686|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dabrafenib-patient-drug-information\" class=\"drug drug_patient\">Dabrafenib: Patient drug information</a></li></ul></div></div>","javascript":null}